Synthetic Biologics Inc (NYSEMKT:SYN):
The company’s RSI reading has hit 69.51. The stock edged higher by 9.50% to close previous trading session at USD 2.19.
The shares of the company fluctuated in the range of USD 0.93 and USD 4.32 in the course of 52 weeks. Over the three months, the company’s shares have declined by -9.47% and in the past one year, it has lost -15.06%. Additionally, the stock’s year to date performance has declined -3.93%. Over the last five days its shares have surged by 13.40% and in the past six months it has moved down -32.93%.
Further, the company is trading at a price to book ratio of 12.22. The stock’s weekly volatility is calculated as 7.42% and monthly volatility as 10.52% with ATR of 0.17, beta of 1.17 and price to cash ratio of 9.61.
Synthetic Biologics Inc (SYN) provided an operational update and reported financial results for the year ended December 31, 2015.
Microbiome-Focused Clinical Program Progress
SYN-010 – Treatment of irritable bowel syndrome with constipation (IBS-C):
- Expect to initiate Phase 3 clinical trial(s) (2H 2016)
- Anticipate requesting end of Phase 2 meeting with FDA (Summer 2016)
- Reported positive topline data from second Phase 2 clinical trial – 8-week extension study (1Q 2016)
o All patients who completed the second study showed a statistically significant decrease in methane production (p=0.002) from the beginning of the first Phase 2 study (Study 1 baseline; Day 1) to the end of the second Phase 2 study (12 weeks of treatment; Day 84), thus meeting the study’s primary endpoint
o Topline data also showed improvements in secondary efficacy endpoints, including:
A statistically significant reduction in the mean IBS Symptom Severity Score (IBS-SSS; p=0.0001) which includes abdominal pain, bloating, stool frequency and quality of life scores, was observed for all patients from Study 1 baseline to the end of the second Phase 2 study
An increase in the percentage of patients identified as Monthly Responders, an FDA-defined composite measure incorporating improvements in complete spontaneous bowel movements and abdominal paini
o No serious adverse events were observed
- Reported positive topline data from first Phase 2 clinical trial – 4-week acute study (4Q 2015)
o SYN-010 met its primary endpoint of lowering breath methane compared to baseline in breath methane-positive IBS-C patients
ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD):
The stock increased by 8.79% to close last trading session at USD 21.53. The company’s shares oscillated in the range of USD 19.68 and USD 21.80 during intraday trade.
A total of 2.92 million shares exchanged hands, above its 3 month average volume of 2.07 million shares. Over the last five days its shares have surged by 5.95% and in the past six months it has moved down -50.31%.
Furthermore, the stock has weekly volatility of 7.18% and monthly volatility of 7.94% with ATR of 1.46. The stock’s RSI is 56.77 and distance from 50-day simple moving average is 2.77%, whereas its distance from 20-day simple moving average is 9.31% and distance from 200-day simple moving average is -37.06%.
ACADIA Pharmaceuticals Inc. (ACAD) a biopharmaceutical company focuses on the development and commercialization of small molecule drugs that address unmet medical needs in central nervous system disorders. Its lead product candidate, NUPLAZID, has completed the Phase III pivotal trials for the treatment of Parkinsons disease psychosis and the Phase II trial for the treatment of schizophrenia, as well as is in Phase II study for the treatment of Alzheimer’s disease psychosis. It also has clinical-stage programs for glaucoma and, in collaboration with Allergan, Inc., for chronic pain. ACADIA Pharmaceuticals Inc. was founded in 1993 and is headquartered in San Diego, California.